Search

everythinglearnresearchcommunity

for

Search:↓

Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stem cells as promising options, while others express doubt due to past disappointments and lack of focused research.

Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The conversation humorously discusses using anal administration of Dutasteride as a novel method for treating hair loss, suggesting it could target DHT production more effectively. It includes satirical comments about the method's potential effects and absurd outcomes.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The user is happy with their hair regrowth after three months of using a 4-in-1 pill containing minoxidil, dutasteride, finasteride, and biotin, along with microneedling and saw palmetto shampoo. They experienced initial shedding but are pleased with the progress and have not had any side effects.

The conversation discusses treatments for androgenetic alopecia, focusing on evidence-based supplements to complement finasteride. Suggestions include oral minoxidil, saw palmetto, pumpkin seed oil, tocotrienols, and various other supplements, while emphasizing the importance of scientific backing and cautioning against saw palmetto if already using finasteride.

The conversation discusses hair loss treatments, focusing on the use of peptides, injections, and topical applications like Minoxidil foam. Users debate the effectiveness of different methods, with some advocating for injections and others supporting topical treatments.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

The user reported positive hair regrowth results after six months of using 0.5 mg finasteride and nanoxidil, despite experiencing initial side effects like testicular pain and changes in libido. They noted that nanoxidil was chosen over minoxidil due to less scalp irritation.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user is struggling with hair loss despite using topical minoxidil, finasteride, and oral dutasteride, and is seeking affordable alternatives to 2.5mg dutasteride. Suggestions include checking for scalp inflammation, considering oral minoxidil, using rosemary oil, and possibly trying saw palmetto, though results may vary.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.

A 21-year-old is experiencing hairline recession and is using finasteride, saw palmetto, gelatin, topical minoxidil with retinoic acid, derma stamping, and scalp massage to address it. Suggestions include adding oral minoxidil, vitamin D3 with K2, and maintaining the current regimen for a year.

Nizoral 2% is popular for maintaining scalp health and reducing inflammation, though its effectiveness for hair loss is debated. Some users combine it with finasteride for better results, while others find it drying or ineffective.

Effective treatments for hair loss include finasteride, dutasteride, RU58841, and minoxidil. Starting treatment early is important, and users discuss different brands, forms, and side effects.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

OP used finasteride 1mg and 2.5mg oral minoxidil since late April, showing hair improvement despite some initial libido issues. Users discussed side effects, costs, and alternative treatments, with OP noting increased facial hair but no significant body hair growth.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A user experienced dry, brittle hair after starting dutasteride and considered switching back to finasteride. Another user advised that the dryness is temporary and shared positive results with dutasteride and oral minoxidil after several months.

A user shared a 15-year experience using minoxidil and finasteride for hair loss, stating that despite never missing a dose, their hairline continued to recede slowly. Other users suggested that the hair loss might be exacerbated by the use of steroids and recommended considering other treatments like dutasteride and RU58841.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

The conversation discusses improving a hair loss treatment stack without using Minoxidil. Microneedling is suggested, Alpecin is deemed ineffective, and there are concerns about the safety of Minoxidil compared to finasteride.

The conversation discusses the potential of verteporfin in treating hair loss, with some users reporting positive results and speculating that it could lead to a cure for baldness. Others are skeptical, and there's a debate on the effectiveness of verteporfin for regrowing hair and reducing transplant scars.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

User experienced hair regrowth after eliminating scalp itch with RU58841. Others discussed itch and hair loss connection, and effectiveness of combining RU58841 with 5AR inhibitors.

A user's progress after three months of taking dutasteride 0.5 mg to treat their hair loss; other users suggested cutting the frizzy hair and adding minoxidil, while others cautioned against it.